The short version of CAS Registry Number fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
=== Comparison to other staple foods === The following table shows the nutrient content of raw plantain and other major staple foods in a raw form on a dry weight basis to account for their different water contents.
from Piedmontese beef) has a place on the specialist market due to its high palatability and tenderness, at least for purebred myostatin-deficient strains the expenses and (especially in cattle) necessity of veterinary supervision place them at a disadvantage in the bulk market.
=== T-cell hypothesis === Populations of regulatory T cells are believed to be responsible for the onset of the disease. When there is a decline of these cells, manifestations of diseases begin to appear, giving an idea of the vital role of these cells in the prevention of autoimmune diseases. Moreover, an additional decrease could, unfortunately, worsen the pathological state and lead to the differentiation of an undifferentiated connective tissue disease into a differentiated connective tissue disease with a poorer prognosis. Due to the wide range of variation in the inclusion criteria of the disease, up to 50% of patients diagnosed with connective tissue disease may have undifferentiated disease of the underlying connective tissue.
He said he supported "bipartisan comprehensive immigration reform", which he had called for during his 2018 gubernatorial campaign. Pritzker also said he supported the deportation of undocumented immigrants who had been convicted of violent crimes, saying, "violent criminals have no place on our streets; if they are undocumented, we want them out of Illinois and out of our country". In 2025, Pritzker spoke out against the Trump administration's Operation Midway Blitz, an operation cracking down on undocumented immigrants in Chicago. He said the operation was targeting law-abiding minority Chicagoans and not cooperating with local authorities.
Sources: en.wikipedia.org
=== Gas cloud composition === Apart from MIC, based on laboratory simulation conditions, the gas cloud most likely also contained chloroform, dichloromethane, hydrogen chloride, methylamine, dimethylamine, trimethylamine, and carbon dioxide that was either present in the tank or was produced in the storage tank when MIC, chloroform, and water reacted. The gas cloud, composed mainly of materials denser than air, stayed close to the ground and spread in a southeast direction affecting the nearby communities. The chemical reactions may have produced a liquid or solid aerosol. Laboratory investigations by CSIR and UCC scientists failed to demonstrate the presence of hydrogen cyanide.
==== Distribution ==== The volume of distribution of THC is large and is approximately 10 L/kg (range 4–14 L/kg), which is due to its high lipid solubility. The plasma protein binding of THC and its metabolites is approximately 95 to 99%, with THC bound mainly to lipoproteins and to a lesser extent albumin. THC is rapidly distributed into well-vascularized organs such as lung, heart, brain, and liver, and is subsequently equilibrated into less vascularized tissue. It is extensively distributed into and sequestered by fat tissue due to its high lipid solubility, from which it is slowly released. THC is able to cross the placenta and is excreted in human breast milk.
Ion milling is a specialized physical etching technique that is a crucial step in the preparation of material analysis techniques. After a specimen goes through ion milling, the surface becomes much smoother and more defined, which allows scientists to study the material much easier. The ion mill generates high-energy particles to remove material off the surface of a specimen, similar to how sand and dust particles wear away at rocks in a canyon to create a smooth surface. Relative to other techniques, ion milling creates much less surface damage, which makes it perfect for surface-sensitive analytical techniques. This article discusses the principle, equipment, applications, and significance of ion milling.
Sources: en.wikipedia.org
==== Mastocytosis ==== Mastocytosis involves both excessive accumulation and activation of mast cells and is considered a primary type of mast cell activation disorder (MCAD). Mastocytosis is a rare clonal mast cell disorder involving rapid, uncontrolled cell growth and the presence of too many mast cells (mastocytes). The most commonly affected organs in mastocytosis are bone marrow, skin, liver, spleen, and lymph nodes. Symptoms of mastocytosis depend upon the organs involved. In 2016, the World Health Organization (WHO) classified mastocytosis as cutaneous (CM, skin only), systemic (SM, involving at least one additional organ) or mast cell sarcoma (MCS, involving rapidly spreading solid tumors). In 2022, WHO divided SM into subcategories which include the less advanced forms of bone marrow mastocytosis (BMM), indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), and the more advanced forms of aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL). Although not always present, mutations in KIT appear to result in uncontrolled growth of MCs. The KITD816V mutation is present in over 90% of mastocytosis patients. It is located in exon 17 in the intracellular tyrosine kinase 2 (TK2) domain. This mutation, as well as expression of either CD2 or CD25 (confirmed by immunostaining or flow cytometry), are characteristic of primary clonal/monoclonal mast cell activation syndrome (CMCAS/MMAS).
US575002A patent on 01.Dec.1897 to Alexander Lodyguine (Lodygin, Russia) describes filaments made of rare metals, amongst them was tungsten. Lodygin invented a process where rare metals such as tungsten can be chemically treated and heat-vaporized onto an electrically heated thread-like wire (platinum, carbon, gold) acting as a temporary base or skeletal form. (US patent 575,002). Lodygin later sold the patent rights to General Electric. In 1902, Siemens developed a tantalum lamp filament that was more efficient than even graphitized carbon filaments since they could operate at higher temperature. Since tantalum metal has a lower resistivity than carbon, the tantalum lamp filament was quite long and required multiple internal supports. The metal filament gradually shortened in use; the filaments were installed with large slack loops. Lamps used for several hundred hours became quite fragile. Metal filaments had the property of breaking and re-welding, though this would usually decrease resistance and shorten the life of the filament. General Electric bought the rights to use tantalum filaments and produced them in the US until 1913. From 1898 to around 1905, osmium was also used as a filament in lamps made by Carl Auer von Welsbach. The metal was so expensive that used lamps could be returned for partial credit. It could not be made for 110 V or 220 V so several lamps were wired in series for use on standard voltage circuits. These were primarily sold in Europe.
Polymers display varying degrees of crystallinity, and many are completely non-crystalline. Glass, some ceramics, and many natural materials are amorphous, not possessing any long-range order in their atomic arrangements. The study of polymers combines elements of chemical and statistical thermodynamics to give thermodynamic and mechanical descriptions of physical properties.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.